Rchr
J-GLOBAL ID：201601013410720955
Update date: Oct. 03, 2024
Li Xia
Li Xia
Affiliation and department：
Research field (4)：
Nanomaterials
, Nanobioscience
, Immunology
, Tumor diagnostics and therapeutics
Research theme for competitive and other funds (3)：
- 2023 - 2026 ナノコンプレックスによる個別化複合がん免疫療法の開発
- 2022 - 2024 低温自己組織化によるがん治療ナノワクチンの開発
- 2009 - 2011 生物学的シグナル分子を担持した癌免疫療法用複合メソポーラスアジュバンド
Papers (81)：
-
Xia Li, Shinya Hattori, Tomohiko Yamazaki, Mitsuhiro Ebara, Naoto Shirahata, Nobutaka Hanagata. Inosine pranobex-derived coordination complexes for self-adjuvant, self-carrier, and self-assembled vaccines in cancer immunotherapy (Front Cover). Applied Materials Today. 2024. 39. 102299
-
Xia Li, Mitsuhiro Ebara, Naoto Shirahata, Tomohiko Yamazaki, Nobutaka Hanagata. Synergistic Effects of Metal-Organic Nanoplatform and Guanine Quadruplex-Based CpG Oligodeoxynucleotides in Therapeutic Cancer Vaccines with Different Tumor Antigens. Vaccines. 2024. 12. 6. 649
-
Xia Li, Naoto Shirahata, Tomohiko Yamazaki, Nobutaka Hanagata. A rapid strategy to develop personalized cancer nanovaccines for different immunogenic tumors. Journal of Clinical Oncology. 2024. 42. 16_suppl. e14670
-
Xiupeng Wang, Yu Sogo, Xia Li. Size Tuning of Mesoporous Silica Adjuvant for One-Shot Vaccination with Long-Term Anti-Tumor Effect. Pharmaceutics. 2024. 16. 4. 516
-
Xiupeng Wang, Motohiro Hirose, Xia Li. TLR7 Agonist-Loaded Gadolinium Oxide Nanotubes Promote Anti-Tumor Immunity by Activation of Innate and Adaptive Immune Responses. Vaccines. 2024. 12. 4. 373
ｍore...
Patents (4)：
Return to Previous Page
